Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...
The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and for office-based surgeries.
A medical expert in infertility discusses how best practices in communicating benefits for fertility treatments and assisted reproductive technology (ART) programs involve clear, concise and ...
Jeffrey Dunn, Pharm.D., MBA, discusses how social determinants of health and population health factors are integrated into decision-making processes for fertility treatments and assisted reproductive ...